A new small molecule inhibitor of the LOXL2 enzyme, developed by Pharmaxis, is safe and holds potential to treat fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non‐alcoholic steatohepatitis (NASH), according to results from a Phase 1 trial. The study (ACTRN12617001564347) enrolled 48 healthy volunteers who were…
LOXL2 Inhibitor PXS-5382A Shows Potential to Treat IPF, Other Fibrotic Diseases in Phase 1 Trial
Redx Pharma announced it soon give an update on early work on a potentially new type of idiopathic pulmonary fibrosis (IPF) treatment, called RXC006, that may help patients with advanced disease. Peter Bunyard, PhD, the company’s head of fibrosis, will present preclinical data at the 2nd Anti-Fibrotic…
It’s no secret that chronic illness complicates the lives of patients, regardless of the disease. While illnesses have many recognized symptoms, only patients are aware of the lesser-known complexities of each one. Since my idiopathic pulmonary fibrosis (IPF) diagnosis, I have been consistently learning and adjusting to what…
Ofev (nintedanib) shows a similar ability to reduce lung function decline in patients with advanced idiopathic pulmonary fibrosis (IPF) as those with milder disease, according to a real-world clinical study. However, a higher number of patients with advanced IPF stopped Ofev treatment. The study, “Efficacy and…
One of my goals as a pulmonary fibrosis patient is to stay as healthy as possible for as long as possible. Regularly exercising has helped me immensely. I actually feel better than I used to. At first, I thought my doctor was crazy when he referred me…
A plant-derived compound called ouabain is a potential treatment for idiopathic pulmonary fibrosis (IPF), according to a recent study. Treatment with ouabain — more commonly used to treat certain heart conditions — alleviated IPF-related symptoms in mice. The study, “Ouabain ameliorates bleomycin induced pulmonary fibrosis by inhibiting…
Lately, I have been taking what feels like an excessive number of sick days, both from work and from day-to-day activities. In the past couple of years, it’s taken time to accept that I must prioritize my body’s needs and slow down or rest when needed has…
A greater decline in lung function prior to treatment start may lead idiopathic pulmonary fibrosis (IPF) patients to stop using Ofev (nintedanib), as might older age, a real-world study from the United Kingdom found. “No predominant reason for discontinuation was identified in this group,” its researchers wrote, but it’s…
Genkyotex’s anti-fibrotic candidate GKT831 appears to be safe and hold therapeutic activity in an ongoing Phase 2 trial in patients with primary biliary cholangitis, an autoimmune-triggered fibrotic disease of the liver. These positive interim results support the development of GKT831 as a possible treatment of other fibrotic diseases,…
Since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in April 2016, I have enjoyed connecting with other patients living with this life-threatening lung disease. For the most part, hearing others’ stories has given me comfort, hope, and encouragement. I believe that the benefits of connecting with my…
